Immune Checkpoint Inhibitor–Related Myocarditis With or Without Concomitant Myopathy: Clinical Findings and Cardiovascular Outcomes
Authors' conclusion
Patients with irMyocarditis and irMyopathy and those with isolated irMyocarditis have distinct biomarker profiles and cardiovascular complications.
Study context
- Population
- Patients with immune checkpoint inhibitor-induced myocarditis, Massachusetts General Brigham, 2015–2023
- Participants
- 101 patients
- Exposure
- irMyocarditis with concomitant immune-related myopathy (irMyopathy) vs isolated irMyocarditis
- irMyocarditis and irMyopathyn = 32
- Outcome
- Acute HF requiring diuresis, significant arrhythmias (ventricular arrhythmias and high-degree AV block), CV and all-cause mortality
- Follow-up
- Index hospitalization
Main finding
As reported in the abstract
Hazard ratio (95% CI)P value
irMyocarditis and irMyopathy vs Isolated irMyocarditissignificant arrhythmias
2.12(1.13–3.97)
P = 0.019Isolated irMyocarditis vs irMyocarditis and irMyopathyacute decompensated HF
5.88(1.45–25)
P = 0.013Observational data: associations, not effects.
Further findings
High-sensitivity troponin T
Creatine kinase
NT-proBNP
Median
| Outcome | irMyocarditis and irMyopathy | Isolated irMyocarditis |
|---|---|---|
| LVEF | 65% | 56% |
- High-sensitivity troponin T: P < 0.001
- Creatine kinase: P < 0.001
- NT-proBNP: P = 0.007
- LVEF: P = 0.008
Original publication
Immune Checkpoint Inhibitor–Related Myocarditis With or Without Concomitant Myopathy: Clinical Findings and Cardiovascular Outcomes. JACC CardioOncol. Published 17 March 2025. doi:10.
Summarised from the published abstract; every number is checked against it